MPC
44
3
EMC
56
-3
FMC
37
-2
RF
67
-2
URBN
50
-2
ADM
36
5
EXPE
93
2
CHRW
54
-2
FOXA
53
3
MUR
42
-2
AVY
54
-4
PHM
65
-5
CB
55
2
BXP
60
5
LEG
43
-7
ROK
64
-2
ADI
51
-3
O
24
2
IRM
52
2
GM
65
-7
MPC
44
3
EMC
56
-3
FMC
37
-2
RF
67
-2
URBN
50
-2
ADM
36
5
EXPE
93
2
CHRW
54
-2
FOXA
53
3
MUR
42
-2
AVY
54
-4
PHM
65
-5
CB
55
2
BXP
60
5
LEG
43
-7
ROK
64
-2
ADI
51
-3
O
24
2
IRM
52
2
GM
65
-7
Financhill
Back

Sarepta Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
49

SRPT
Sarepta Therapeutics

Last Price:
130.47
Seasonality Move:
14.88%

7 Day Trial

ALL ACCESS PASS

$ 7

Say this - unlock as much as $1,250 every Friday

Click here for full details.

Sarepta Therapeutics Price Quote

$130.47
-0.03 (13.8%)
(Updated: November 27, 2024 at 5:41 AM ET)

Sarepta Therapeutics Key Stats

Sell
49
Sarepta Therapeutics (SRPT) is a Sell
Day range:
$115.75 - $131.00
52-week range:
$78.67 - $173.25
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
8.00
P/B ratio:
10.21%
Volume:
3.4M
Avg. volume:
1.1M
1-year change:
57.48%
Market cap:
$12.5B
Revenue:
$1.2B
EPS:
$1.54

How Much Does Sarepta Therapeutics Make?

Is Sarepta Therapeutics Growing As A Company?

  • What Is Sarepta Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.41%
  • What Is Sarepta Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sarepta Therapeutics Stock Price Performance

What Is Sarepta Therapeutics 52-Week High & Low?

Sarepta Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sarepta Therapeutics?

Is Sarepta Therapeutics Cash Flow Positive?

  • What Is SRPT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$352.5M
  • What Is Sarepta Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $77.8M
  • What Is Sarepta Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$72.9M

Sarepta Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SRPT return on invested capital is 5.51%
  • What Is Sarepta Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 3.67%
  • What Is SRPT Return On Equity?
    ROE is a measure of profitability and is 12.48%

Sarepta Therapeutics Earnings Date & Stock Price

Sarepta Therapeutics Competitors

  • Who Are Sarepta Therapeutics's Competitors?
    Below is a list of companies who compete with Sarepta Therapeutics or are related in some way:
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Eli Lilly and Co (LLY)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Viking Therapeutics Inc (VKTX)
    • Vertex Pharmaceuticals Inc (VRTX)

Sarepta Therapeutics Dividend Yield

Sarepta Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 66.97%
Revenue: 40.79% 15.33%

Analyst Recommendations

Buy Recommendations: 12
Hold Recommendations: 0
Sell Recommendations: 1
Price Target: 184.46
Upside from Last Price: 41.35%

Major Shareholders

  • How many SRPT shares are owned by institutional investors?
    147.3M SRPT shares are owned by institutional investors
  • How many SRPT shares are owned by insiders?
    15.5M SRPT shares are owned by insiders